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cause there are no established protocols for primary or recurrent
disease. Herein, we present a case of a woman whose abdominopelvic
IMT was surgically debulked and treated with various chemotherapeu-
tic agents, yet metastasized to the bone and liver, with extensive perito-
neal sarcomatosis, within 15 months after diagnosis.
Case presentation
A previously healthy nulliparous 28-year old Caucasianwoman pre-
sented to her primary care physician with a two-week history of post-family history of cancer. Physical examination revealed a palpableIntroduction
Inﬂammatory myoﬁbroblastic tumor (IMT) is a rare mesenchymal
tumor that is more common in children and young adults, with a medi-
an age of 9 years old and slight predominance in females (Unni and
Hogendoom, 2002). Although IMT can involve any location in the
body, the abdominopelvic region, retroperitoneum and lungs are most
commonly affected (Cofﬁn et al., 1995). Grossly, IMTs appear ﬁrm or
ﬂeshywith awhite or tan surface and can resemble other benign orma-
lignant tumors in appearance such as leiomyoma, leiomyosarcoma, and
inﬂammatory liposarcoma (Rabban et al., 2005). Histologically, IMTs
have spindle cell proliferation with inﬂammatory inﬁltrates of plasma
cells, lymphocytes, and eosinophils (Gleason and Hornick, 2008). Im-
munohistochemical (IHC) staining will typically show reactivity for
vimentin, smooth muscle actin and desmin (Unni and Hogendoom,
2002). Approximately 50% of IMTs will have IHC cytoplasmic positivity
for anaplastic lymphoma kinase (ALK), which can be used to differenti-
ate the tumor from the ALK-negative leiomyoma and leiomyosarcoma
(Unni and Hogendoom, 2002; Rabban et al., 2005).
IMT is currently regarded as a neoplasm of intermediate biologic
potential because of its tendency to locally recur but rarely metastasizeer,MN55905, USA. Fax:+1 507
-Gamez).
. This is an open access article underprandial abdominal pain. She was on oral contraceptives and had no
abdominal mass. The patient's CA 125 was 71 U/mL with negative
AFP. Ultrasound and computed tomography (CT) scan showed ascites
and multiple peritoneal masses (Fig. 1A), with the largest mass in the
right upper quadrantmeasuring 6.5 × 8 cm. Shewas diagnosedwith ab-
dominal carcinomatosis and referred to gynecologic oncology.
Due to the uniform appearance of the masses, the differential diag-
noses of disseminated leiomyomatosis and sarcoma were considered.
The patient underwent an exploratory laparotomy which revealed ex-
tensive solid masses involving multiple viscera with impending ob-
struction (Fig. 1B). Tumor cytoreduction required resection of the
sigmoid colon, two segments of ileum, the omentum, and the appendix.
The masses were discrete and well-circumscribed, but deeply inﬁltra-
tive into the adjacent muscularis of the small bowel and colon,
prohibiting local excision without resection of the enteric tract. Despite
the previously described resections to prevent obstruction and removal
of several 8–10 cmmasses from the ileal and jejunalmesenteries, sever-
al dozen nodules measuring up to 2 cm in size remained on themesen-
teric border throughout the ileum and jejunum, prohibiting further
resection. The uterus, ovaries and fallopian tubes were normal in ap-
pearance and left in situ as the patient desired fertility preservation.
Final pathologic analysis revealed the sigmoid colon, ileum and
omentum to contain numerous nodules of IMT ranging in size from
0.5 cm to 13.5 cm in greatest dimension involving the serosa and mes-
entery (Fig. 1C). Histologically, the tumor was composed of a cellular
proliferation of long, tapered, spindled cells forming loose fascicles in
an edematous stroma with prominent lymphoplasmacytic inﬁltrate.
There were occasional mitotic ﬁgures, including atypical forms. Somethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. A) Preoperative CT image demonstrating multiple solid peritoneal masses. B) Intraoperative ﬁndings of multiple solid masses involving pelvic and abdominal viscera. C) Resected
sigmoid colon with numerous nodules of inﬂammatory myoﬁbroblastic tumor ranging from 1.0 cm to 13.5 cm in greatest dimension involving the serosa and mesentery.
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tochemistry, the neoplastic cells were weakly reactive for smooth
muscle actin (SMA) but negative for S100, desmin, KIT, anaplastic lym-
phoma kinase (ALK-1), CD34 and OSCAR-keratin, consistent with IMT
(Fig. 2). The ascitic ﬂuid and multiple lymph nodes from the omentum
were negative for malignancy.Fig. 2. Inﬂammatorymyoﬁbroblastic tumor. A) Hematoxylin and eosin stained preparation, 200×
an edematous stromawith prominent lymphoplasmacytic inﬁltrate and occasional atypical mito
tumor cell atypia. C), D), E) Immunohistochemistry, 200× magniﬁcation, showing neoplastic cePostoperatively, the patient was started on prednisone for three
months and experienced tumor progression. She was switched to ima-
tinib for amonth. During this time, the patientwas noted to have signif-
icant pelvic pain and ureteral compression; she had bilateral ureteral
stents placed with relief of symptoms. She was then started on liposo-
mal doxorubicin; however, she had continued progression. The patientmagniﬁcation, showing IMTwith long, tapered, spindled cells arranged in loose fascicles in
tic ﬁgure. B) Hematoxylin and eosin stain, 600×magniﬁcation, demonstrating ganglion-like
lls to be negative for ALK-1 and desmin, but weakly positive for SMA, respectively.
Fig. 3. A) MRI shows sclerotic metastases to L4 vertebrae body (arrow) 14 months after initial diagnosis and surgical debulking, despite various systemic therapies. B) CT scan shows
hepatic metastases (arrow) and extensive peritoneal sarcomatosis 15 months after diagnosis.
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response. She subsequently was placed on oral pazopanib, initially
experiencing stable disease, although the patient began noting increas-
ing back and rib pain. Four months after starting pazopanib, magnetic
resonance imaging (MRI) showed metastases to the L4 vertebral body
(Fig. 3A). Consequently, the patientwas treatedwith palliative radiation
therapy. She completed 5 of a planned 10 fractionswhen she developed
severe abdominal pain for which she presented to the emergency room.
CT revealed extensive hepatic metastases and peritoneal sarcomatosis
(Fig. 3B). She was also found to have polymicrobial peritonitis second-
ary to a small bowel perforation from tumor invasion. The patient
elected for hospice care and expired 5 days later, 15 months after
diagnosis.
Discussion
In its ﬁrst description in 1939, IMT was considered a benign disease
process (Gleason and Hornick, 2008). In the gynecologic literature, IMT
has been described also in the uterus as a benign tumor (Rabban et al.,
2005; Fuehrer et al., 2012). However, over the past two decades, case
series have illustrated the potentially aggressive course of the disease,
including a 37% rate of local recurrence and 11% rate of metastases
(Cofﬁn et al., 1995; Meis and Enzinger, 1991). Subsequently, IMT is
now classiﬁed by the World Health Organization as an intermediate,
rarely metastasizing tumor (Unni and Hogendoom, 2002). While IMT
can occur in any site in the body, primary abdominopelvic IMT is asso-
ciated with a higher local recurrence rate of 25% compared to only 2%
for primary pulmonary IMT (Gleason and Hornick, 2008; Cofﬁn et al.,
2007). When it does metastasize, the most frequent site of metastasis
is the lungs and the most common sites of extrapulmonary IMT metas-
tases are the mesentery and omentum (Unni and Hogendoom, 2002).
Patients with abdominopelvic IMT typically present with nonspecif-
ic symptoms such as abdominal pain, loss of appetite and weight, and a
palpable mass (Unni and Hogendoom, 2002). Clinical presentation may
also include fever, iron deﬁciency anemia and elevated sedimentation
rate. With these symptoms, the differential diagnoses of peritoneal car-
cinomatosis, gastrointestinal stromal tumor (GIST) or lymphoma are
often considered (Gleason and Hornick, 2008). In a young woman as
in our patient, the additional consideration of disseminated peritoneal
leiomyomatosis or leiomyosarcoma should be excluded (Rabban et al.,
2005). In particular, themyxoid variant of leiomyosarcoma can be difﬁ-
cult to distinguish from IMT due to a similar well-circumscribed grossappearance and hypocellular pattern (Rabban et al., 2005). In addition,
immunohistochemical staining for ALK-1, negative in leiomyosarcoma,
may not be helpful in differentiating certain IMT, such as our patient's
ALK-1 negative tumors, from leiomyosarcoma (Fuehrer et al., 2012).
The occurrence of extrapulmonary IMT metastases is rare and cap-
tured in only a handful of case series and reports (Meis and Enzinger,
1991; Morotti et al., 2005).With potential for IMTs to behave like a sar-
coma (Hagenstad et al., 2003), there is a need to distinguish malignant
disease from benign to establish appropriate management. Previous
studies on prognostic indicators in IMT have examined morphology
and genetics, suggesting that aneuploidy, p53 overexpression and cellu-
lar atypia are associatedwith progression of disease (Meis and Enzinger,
1991; Hussong et al., 1999). Histologic features described as associated
with aggressive IMT are polygonal/ganglion-like round cells, increased
cellularity, vesicular chromatin, prominent nucleoli, and atypicalmitotic
ﬁgures; the presence of atypical mitotic ﬁgures has been proposed as
themost speciﬁc feature of aggressive tumors (Cofﬁn et al., 2007). A re-
cent promising prognostic factor that has been supported is ALK-1 im-
munohistochemistry. ALK gene rearrangements have been identiﬁed
in 50–75% of extrapulmonary IMTs and this has strengthened the con-
cept of IMT as a sarcoma variant (Cofﬁn et al., 2001, 2007). Furthermore,
studies have suggested that ALK-negative IMTs may follow a more ag-
gressive disease course with increased risk of metastasis (Cofﬁn et al.,
2007; Jiang et al., 2009). Thus, ALK1 immunohistochemistry may be
helpful in determining prognosis. Whether ALK-positive and ALK nega-
tive tumors are distinct disease entities with overlapping morphologic
features is a question of debate.
Surgical debulkingwith complete excision is the treatment of choice
for IMTs and is often curative. However, the ability to achieve complete
surgical excision depends on the site of the lesion, multinodularity,
involvement of other organs and proximity to vital structures. For the
unresectable or recurrent IMT, systemic treatments have provided
inconsistent results. Systemic therapies that have been tried with
varying success include NSAIDs, cyclooxygenase 2 inhibitors, steroids,
radiation therapy, and various chemotherapeutic agents, including cis-
platin, Adriamycin,methotrexate, vincristine, carboplatin and paclitaxel
(Cofﬁn et al., 1995). Curative options remain limited for patients with
aggressive metastatic disease.
Current research has shifted to target gene therapy for treatment.
For the IMT expressing ALK, there are now targeted therapies, such as
crizotinib, an ALK inhibitor, which has been used to treat aggressive dis-
ease in recent case reports (Butrynski et al., 2010). Crizotinib was ﬁrst
12 S. Kim et al. / Gynecologic Oncology Reports 12 (2015) 9–12approved for the treatment of ALK-positive non-small cell lung cancer
(NSCLC) in 2011. In a meta-analysis of six clinical trials for treatment
of ALK-positive NSCLC, crizotinib treatment demonstrated an objective
response rate (ORR) of 61.2% (Qian et al., 2014) and appears to be a rea-
sonable option for ALK-positive IMT (Butrynski et al., 2010). For the
ALK-negative IMT, targeting kinase fusion genes is being explored
(Lovly et al., 2014).
In conclusion, IMT is a rare tumor of intermediate malignant poten-
tial. Some tumors act in an aggressive fashion. Surgical debulking re-
mains the primary treatment and determination of ALK expression
may help triage patients to adjuvant therapies. Additional research on
targeted therapies for this disease appears promising.
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